Translated title of the contribution: New drugs on the market August-October 1992

M. Romero, M. G. Franzosi

Research output: Contribution to journalArticlepeer-review


Among the 7 new molecular entities marketed during this period only two have innovative potential. The first is finasteride, an inhibitor of 5-alfa-reductase which has been proven effective in reducing the size of prostate and related symptoms in men with prostatic hypertrophy. While the magnitude of its effects is probably negligible for patients with only modest symptoms, the drug may be of advantage in subjects with moderate or severe symptoms who are at risk for surgery or desire to postpone it. Anti-endotoxin monoclonal antibodies can reduce mortality when used soon in patients with septic shock from Gram-negative bacteria. Their use is limited by the difficulty to identify in due time the relatively limited subset of patients that can benefit from treatment and by their very high cost.

Translated title of the contributionNew drugs on the market August-October 1992
Original languageItalian
Pages (from-to)1-6
Number of pages6
JournalRicerca e Pratica
Issue number49
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'New drugs on the market August-October 1992'. Together they form a unique fingerprint.

Cite this